Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims 1-22:

1. (currently amended) A pharmaceutical composition for oral administration including tinidazole and fluconazole or a stereoisomer or a stereoisomeric uniform mixture thereof, comprising from about 50 to less than 150 mg fluconazole and from about 1000 to less than 2000 mg tinidazole in a unit dose.

2. (currently amended) A pharmaceutical composition characterized by secnidazole and fluconazole or a stereoisomer or a stereoisomeric mixture thereof, comprising a unit dosage having a uniform mixture ~~consisting essentially of~~ from about 50 to less than 150 mg of fluconazole and from about 1000 to less than 2000 mg of secnidazole.

3. (previously presented) The pharmaceutical composition according to Claim 2, characterized by a percent by weight of 75% ± 20% secnidazole and a percent by weight of 6% ± 2% fluconazole.

4. (cancelled)

5. (previously presented) The pharmaceutical composition according to Claim 3, characterized by a tablet form.

6. (previously presented) The pharmaceutical composition according to Claim 2, characterized by a vehicle mixture of acceptable pharmaceutical vehicles that comprises microcrystalline cellulose, sodium glycolate of starch, polyvinylpyrrolidone, magnesium stearate and white opadry.

7. (cancelled)

8. (cancelled)

9. (cancelled)

10. (cancelled)

11. (cancelled)

12. (cancelled)

13. (previously presented) The pharmaceutical composition according to Claim 1, characterized by a percent by weight of 75% ± 20% tinidazole and a percent by weight of 6% ± 2% fluconazole.

14. (cancelled)

15. (previously presented) The pharmaceutical composition according to Claim 13, characterized by a tablet form.

16. (previously presented) The pharmaceutical composition according to Claim 1, characterized by a vehicle mixture of acceptable pharmaceutical vehicles that comprises microcrystalline cellulose, sodium glycolate of starch, polyvinylpyrrolidone, magnesium stearate and white opadry.

17. (previously presented) The pharmaceutical composition according to Claim 1, characterized by a percent by weight of 75% tinidazole.

18. (previously presented) The pharmaceutical composition according to Claim 2, characterized by a percent by weight of 75% secnidazole.

19. (previously presented) The pharmaceutical composition according to Claim 1, characterized by a percent by weight of 5.7% fluconazole.

20. (previously presented) The pharmaceutical composition according to Claim 2, characterized by a percent by weight of 5.7% fluconazole.

21. (previously presented) The pharmaceutical composition according to Claim 1, wherein the composition is characterized by about 112.5 mg of fluconazole and about 1.5 g of tinidazole.

22. (previously presented) The pharmaceutical composition according to Claim 2, wherein the composition is characterized by about 112.5 mg of fluconazole and about 1.5 g of secnidazole.